Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial
- 1Department of Medical Oncology, Fujian Medical University Union Hospital
Abstract
Background Anti-epidermal growth factor receptor (EGFR) antibodies are widely used in the treatment of RAS wild-type metastatic colorectal cancer (mCRC) across various lines of therapy, including after disease progression. However, evidence from randomized controlled trials regarding the efficacy of cetuximab rechallenge in patients who initially responded to prior cetuximab but subsequently progressed after a cetuximab-free interval remains limited. Methods This single-center, prospective, exploratory randomized trial (ChiCTR1900026961) evaluated cetuximab plus irinotecan rechallenge versus regorafenib in patients with RAS wild-type, microsatellite-stable mCRC who had previously responded to then progressed off cetuximab. Progression-free survival (PFS) was the primary endpoint, with overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety as secondary endpoints. Univariate and multivariate Cox regression analyses were performed to identify potential prognostic factors, and an exploratory nomogram was developed for hypothesis generation. Results Among 68 randomized patients, cetuximab plus irinotecan rechallenge was associated with longer median PFS and OS than regorafenib. The DCR and ORR were numerically higher in the rechallenge group. Median PFS was 5.5 months versus 2.6 months, and median OS was 18.8 months versus 10.4 months. Adverse events in the cetuximab group were predominantly grade 1–2 and manageable with supportive care. Univariate and multivariate analyses identified age, ECOG status, and cetuximab-free interval as potential prognostic factors. An exploratory nomogram was constructed based on these factors. Conclusions These findings suggest that cetuximab plus irinotecan rechallenge may be associated with clinical benefit and acceptable toxicity in selected patients with RAS/BRAF wild-type mCRC. The exploratory nomogram requires further validation. These results support further investigation of rechallenge strategies and biomarker-guided approaches in advanced CRC. Trial registration This study was registered with the Chinese Clinical Trial Registry on October 27, 2019 (registration number: ChiCTR1900026961).
Related
- Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis
- Proteinuria with extended VEGF inhibitor therapy in RAS-mutant metastatic colorectal cancer: incidence, interruptions, and exploratory survival analysis.
- FOLFOX-HAIC plus regorafenib for the treatment of unresectable colorectal liver metastases refractory to first and second-line systemic chemotherapy
- Association between primary-site surgery and overall survival in non-metastatic and metastatic colorectal cancer: a population-based study using the Surveillance, Epidemiology, and End Results database
- HER3 mediates metabolic reprogramming in metastatic colorectal and pancreatic cancer
BibTeX
@article{chen2026efficacy,
title = {{Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial}},
author = {Hao Chen and Tao Jiang and Han Wang and Jianwei zheng and Bin Du and Xiaojiao Weng and Na Yao and Yingjiao Zhu and Qing Liu and Fangyu Lin and Xinli Wang and Xiaoyan Lin},
journal = {BMC Cancer},
year = {2026},
month = jul,
doi = {10.1186/s12885-026-16491-4},
url = {https://doi.org/10.1186/s12885-026-16491-4},
note = {CC BY},
}
RIS
TY - JOUR
TI - Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial
AU - Hao Chen
AU - Tao Jiang
AU - Han Wang
AU - Jianwei zheng
AU - Bin Du
AU - Xiaojiao Weng
AU - Na Yao
AU - Yingjiao Zhu
AU - Qing Liu
AU - Fangyu Lin
AU - Xinli Wang
AU - Xiaoyan Lin
PY - 2026
DA - 2026/07/01
JO - BMC Cancer
DO - 10.1186/s12885-026-16491-4
UR - https://doi.org/10.1186/s12885-026-16491-4
AB - Background Anti-epidermal growth factor receptor (EGFR) antibodies are widely used in the treatment of RAS wild-type metastatic colorectal cancer (mCRC) across various lines of therapy, including after disease progression. However, evidence from randomized controlled trials regarding the efficacy of cetuximab rechallenge in patients who initially responded to prior cetuximab but subsequently progressed after a cetuximab-free interval remains limited. Methods This single-center, prospective, exploratory randomized trial (ChiCTR1900026961) evaluated cetuximab plus irinotecan rechallenge versus regorafenib in patients with RAS wild-type, microsatellite-stable mCRC who had previously responded to then progressed off cetuximab. Progression-free survival (PFS) was the primary endpoint, with overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety as secondary endpoints. Univariate and multivariate Cox regression analyses were performed to identify potential prognostic factors, and an exploratory nomogram was developed for hypothesis generation. Results Among 68 randomized patients, cetuximab plus irinotecan rechallenge was associated with longer median PFS and OS than regorafenib. The DCR and ORR were numerically higher in the rechallenge group. Median PFS was 5.5 months versus 2.6 months, and median OS was 18.8 months versus 10.4 months. Adverse events in the cetuximab group were predominantly grade 1–2 and manageable with supportive care. Univariate and multivariate analyses identified age, ECOG status, and cetuximab-free interval as potential prognostic factors. An exploratory nomogram was constructed based on these factors. Conclusions These findings suggest that cetuximab plus irinotecan rechallenge may be associated with clinical benefit and acceptable toxicity in selected patients with RAS/BRAF wild-type mCRC. The exploratory nomogram requires further validation. These results support further investigation of rechallenge strategies and biomarker-guided approaches in advanced CRC. Trial registration This study was registered with the Chinese Clinical Trial Registry on October 27, 2019 (registration number: ChiCTR1900026961).
SN - 1471-2407
ER -